GlassScriptPhysician profile
Samantha E Fish
NPI 1750165262
$2,298.88
in general payments reported to CMS, 2019-2025
37 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $89.58 · 2024: $1,036 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.37 |
| Education | $119.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $216.82 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $211.84 | 2024-2025 | Enhertu, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $168.85 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $153.97 | 2024 | Jakafi |
| Daiichi Sankyo INC. | $145.74 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Genzyme Corporation | $115.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.39 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Pfizer INC. | $104.06 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $102.00 | 2023-2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $81.92 | 2023-2025 | Fotivda |
| Janssen Biotech, INC. | $80.60 | 2024-2025 | Darzalex, Rybrevant, Talvey |
| Stemline Therapeutics INC. | $66.48 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $64.35 | 2025 | |
| Novocure INC. | $62.04 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $58.95 | 2025 | Xt Cdx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $46.21 | 2024-2025 | Loqtorzi |
| Genentech USA, INC. | $45.84 | 2024-2025 | Polivy, Itovebi |
| Eisai INC. | $45.61 | 2024 | |
| Taiho Oncology, INC. | $41.39 | 2024-2025 | |
| Celgene Corporation | $36.58 | 2024 | Pomalyst |
| Jazz Pharmaceuticals INC. | $32.78 | 2025 | |
| Sobi, INC | $32.03 | 2024-2025 | |
| Astellas Pharma US INC | $29.18 | 2025 | Vyloy, Xtandi |
| Abbvie INC. | $27.10 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $22.63 | 2025 | Danziten |
| Sun Pharmaceutical Industries INC. | $22.54 | 2024 | |
| Blueprint Medicines Corporation | $22.22 | 2025 | Ayvakit |
| Janssen Pharmaceuticals, INC | $20.51 | 2025 | |
| Shield Therapeutics INC | $18.72 | 2023 | |
| Recordati_rare_diseases_inc. | $17.42 | 2025 | Enjaymo |
| Tersera Therapeutics LLC | $17.31 | 2025 | Zoladex |
| Fennec Pharmaceuticals, INC. | $14.72 | 2025 | Fyarro |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2025 | |
| Glaxosmithkline, LLC. | $13.55 | 2025 | Ojjaara |
| Kyowa Kirin, INC. | $13.17 | 2024 | Poteligeo |
| Servier Pharmaceuticals LLC | $13.12 | 2024 | |
| Legend Biotech USA INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.